Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

Solera et al., American Journal of Transplantation, doi:10.1016/j.ajt.2024.03.011
Mar 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case 26% Improvement Relative Risk Tixagevimab/c..  Solera et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 1,975 patients in Canada Lower severe cases with tixagevimab/cilgavimab (not stat. sig., p=0.48) c19early.org Solera et al., American J. Transplanta.., Mar 2024 Favorstixagevimab/ci.. Favorscontrol 0 0.5 1 1.5 2+
38th treatment shown to reduce risk in May 2022, now with p = 0.000029 from 17 studies, recognized in 31 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 109 treatments. c19early.org
Retrospective 1,975 solid organ transplant recipients with COVID-19 showing lower risk of severe cases with tixagevimab/cilgavimab prophylaxis, without statistical significance.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.
risk of severe case, 25.6% lower, RR 0.74, p = 0.48, treatment 7 of 156 (4.5%), control 283 of 1,819 (15.6%), NNT 9.0, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Solera et al., 31 Mar 2024, retrospective, Canada, peer-reviewed, median age 57.5, 12 authors. Contact: jtsolera@gmail.com, deepali.kumar@uhn.ca.
This PaperTixagev../c..All
Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023
Javier T Solera, Berta G Árbol, Ankit Mittal, Victoria Hall, Tina Marinelli, Ilona Bahinskaya, Nazia Selzner, Michael Mcdonald, Jeffrey Schiff, Aman Sidhu, Atul Humar, Deepali Kumar
American Journal of Transplantation, doi:10.1016/j.ajt.2024.03.011
solid organ transplant outcomes vaccination mRNA vaccines antivirals bivalent booster vaccines remdesivir
Declaration of competing interest Deepali Kumar has received clinical trial grants from GSK, Roche, and consultancy fees from GSK, Roche, Merck, Takeda, Exevir, and Allovir. Atul Humar has received clinical trial grants from Merck and consultancy fees from Merck and Takeda. The other authors have no conflicts of interest to disclose. Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajt.2024.03.011.
References
Arora, Kempf, Nehlmeier, Omicron sublineage BQ.1.1 resistance to monoclonal antibodies, Lancet Infect Dis, doi:10.1016/S1473-3099(22)00733-2
Banjongjit, Lertussavavivat, Paitoonpong, The predictors for severe SARS-CoV-2 Omicron (B.1.1.529) and pre-Omicron variants infection among kidney transplant recipients, Transplantation, doi:10.1097/TP.0000000000004361
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19final [report, N Engl J Med, doi:10.1056/NEJMoa2007764
Brenner, Ungaro, Gearry, Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry, Gastroenterology, doi:10.1053/j.gastro.2020.05.032
Chen, Luo, Mei, Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and metaanalysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2022.12.004
Clarke, Wiemken, Korenblat, Excess mortality among solid organ transplant recipients in the United States during the COVID-19 pandemic, Transplantation, doi:10.1097/TP.0000000000004341
Dauriat, Beaumont, Nguyen, Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study, Eur Respir J, doi:10.1183/13993003.00502-2022
Fishbane, Hirsch, Nair, Special considerations for Paxlovid treatment among transplant recipients with SARS-CoV-2 infection, Am J Kidney Dis, doi:10.1053/j.ajkd.2022.01.001
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Heldman, Kates, Fisher, Limaye, Immunosuppression in solid organ transplant recipients with Covid-19: more data, but still complicated, Transpl Infect Dis, doi:10.1111/tid.13650
Heldman, Kates, Safa, Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic, Am J Transplant, doi:10.1111/ajt.16840
Jurdi, Morena, Cote, Bethea, Azzi et al., Tixagevimab/ cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave, Am J Transplant, doi:10.1111/ajt.17128
Kaminski, Gigan, Vermorel, COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders, Kidney Int, doi:10.1016/j.kint.2022.07.008
Kates, Haydel, Florman, Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study, Clin Infect Dis, doi:10.1093/cid/ciaa1097
Levin, Ustianowski, Wit, Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19, N Engl J Med, doi:10.1056/NEJMoa2116620
Linares, Cofan, Diekmann, A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients, PLoS One, doi:10.1371/journal.pone.0247251
Malahe, Hoek, Dalm, Clinical characteristics and outcomes of immunocompromised patients with coronavirus disease 2019 caused by the omicron variant: A prospective, observational study, Clin Infect Dis, doi:10.1093/cid/ciac571
Overvad, Koch, Jespersen, Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-a Danish nationwide cohort study, Am J Transplant, doi:10.1111/ajt.17142
Pereira, Mohan, Cohen, COVID-19 in solid organ transplant recipients: initial report from the US epicenter, Am J Transplant, doi:10.1111/ajt.15941
Planas, Bruel, Staropoli, Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies, bioRxiv, doi:10.1101/2022.11.17.516888
Qu, Evans, Faraone, Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ, BA, doi:10.1101/2022.10.19.512891
Solera, Arbol, Alshahrani, Impact of vaccination and early monoclonal antibody therapy on coronavirus disease 2019 outcomes in organ transplant recipients during the omicron wave, Clin Infect Dis, doi:10.1093/cid/ciac324
Solera, Arbol, Bahinskaya, Marks, Humar et al., Shortcourse early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave, Am J Transplant, doi:10.1111/ajt.17199
Solera, Arbol, Ferreira, Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab, Lancet Infect Dis, doi:10.1016/S1473-3099(23)00208-6
Solera, Ierullo, Arbol, Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients, Lancet Infect Dis, doi:10.1016/S1473-3099(23)00357-2
Uraki, Ito, Furusawa, Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB, Lancet Infect Dis, doi:10.1016/S1473-3099(22)00816-7
Villanego, Vigara, Alonso, Trends in COVID-19 outcomes in kidney transplant recipients during the period of Omicron variant predominance, Transplantation, doi:10.1097/TP.0000000000004126
Wang, Iketani, Li, Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, Cell, doi:10.1016/j.cell.2022.12.018
Weiss, Hendrickx, Stensgaard, Jellingsø, Sommer, Kidney transplant and dialysis patients remain at increased risk for succumbing to COVID-19, Transplantation, doi:10.1097/TP.0000000000004462
{ 'indexed': {'date-parts': [[2024, 5, 1]], 'date-time': '2024-05-01T00:21:36Z', 'timestamp': 1714522896149}, 'reference-count': 31, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T00:00:00Z', 'timestamp': 1709251200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T00:00:00Z', 'timestamp': 1709251200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/legal/tdmrep-license'}, { 'start': { 'date-parts': [[2024, 3, 15]], 'date-time': '2024-03-15T00:00:00Z', 'timestamp': 1710460800000}, 'content-version': 'vor', 'delay-in-days': 14, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100000014', 'name': 'Canadian Blood Services', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': ['amjtransplant.org', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['American Journal of Transplantation'], 'published-print': {'date-parts': [[2024, 3]]}, 'DOI': '10.1016/j.ajt.2024.03.011', 'type': 'journal-article', 'created': {'date-parts': [[2024, 3, 17]], 'date-time': '2024-03-17T01:14:03Z', 'timestamp': 1710638043000}, 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023'], 'prefix': '10.1016', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6833-6625', 'authenticated-orcid': False, 'given': 'Javier T.', 'family': 'Solera', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2880-3780', 'authenticated-orcid': False, 'given': 'Berta G.', 'family': 'Árbol', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7666-6234', 'authenticated-orcid': False, 'given': 'Ankit', 'family': 'Mittal', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-9353-0059', 'authenticated-orcid': False, 'given': 'Victoria', 'family': 'Hall', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0404-787X', 'authenticated-orcid': False, 'given': 'Tina', 'family': 'Marinelli', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0009-0004-4273-2207', 'authenticated-orcid': False, 'given': 'Ilona', 'family': 'Bahinskaya', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9435-2597', 'authenticated-orcid': False, 'given': 'Nazia', 'family': 'Selzner', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8026-9274', 'authenticated-orcid': False, 'given': 'Michael', 'family': 'McDonald', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0493-0646', 'authenticated-orcid': False, 'given': 'Jeffrey', 'family': 'Schiff', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4817-1533', 'authenticated-orcid': False, 'given': 'Aman', 'family': 'Sidhu', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-1751-7159', 'authenticated-orcid': False, 'given': 'Atul', 'family': 'Humar', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-1961-0477', 'authenticated-orcid': False, 'given': 'Deepali', 'family': 'Kumar', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '11', 'key': '10.1016/j.ajt.2024.03.011_bib1', 'doi-asserted-by': 'crossref', 'first-page': '2627', 'DOI': '10.1111/ajt.17142', 'article-title': 'Outcomes following SARS-CoV-2 infection in individuals with and without ' 'solid organ transplantation—a Danish nationwide cohort study', 'volume': '22', 'author': 'Overvad', 'year': '2022', 'journal-title': 'Am J Transplant'}, { 'issue': '12', 'key': '10.1016/j.ajt.2024.03.011_bib2', 'doi-asserted-by': 'crossref', 'first-page': '2399', 'DOI': '10.1097/TP.0000000000004341', 'article-title': 'Excess mortality among solid organ transplant recipients in the United ' 'States during the COVID-19 pandemic', 'volume': '106', 'author': 'Clarke', 'year': '2022', 'journal-title': 'Transplantation'}, { 'issue': '11', 'key': '10.1016/j.ajt.2024.03.011_bib3', 'doi-asserted-by': 'crossref', 'first-page': 'e4090', 'DOI': '10.1093/cid/ciaa1097', 'article-title': 'Coronavirus disease 2019 in solid organ transplant: a multicenter ' 'cohort study', 'volume': '73', 'author': 'Kates', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'issue': '3', 'key': '10.1016/j.ajt.2024.03.011_bib4', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0247251', 'article-title': 'A\xa0propensity score-matched analysis of mortality in solid organ ' 'transplant patients with COVID-19 compared to non-solid organ ' 'transplant patients', 'volume': '16', 'author': 'Linares', 'year': '2021', 'journal-title': 'PLoS One'}, { 'issue': '5', 'key': '10.1016/j.ajt.2024.03.011_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1136', 'DOI': '10.1097/TP.0000000000004462', 'article-title': 'Kidney transplant and dialysis patients remain at increased risk for ' 'succumbing to COVID-19', 'volume': '107', 'author': 'Weiss', 'year': '2023', 'journal-title': 'Transplantation'}, { 'issue': '12', 'key': '10.1016/j.ajt.2024.03.011_bib6', 'doi-asserted-by': 'crossref', 'first-page': 'e520', 'DOI': '10.1097/TP.0000000000004361', 'article-title': 'The predictors for severe SARS-CoV-2 Omicron (B.1.1.529) and ' 'pre-Omicron variants infection among kidney transplant recipients', 'volume': '106', 'author': 'Banjongjit', 'year': '2022', 'journal-title': 'Transplantation'}, { 'issue': '2', 'key': '10.1016/j.ajt.2024.03.011_bib7', 'doi-asserted-by': 'crossref', 'first-page': '481', 'DOI': '10.1053/j.gastro.2020.05.032', 'article-title': 'Corticosteroids, but not TNF antagonists, are associated with adverse ' 'COVID-19 outcomes in patients with inflammatory bowel diseases: results ' 'from an international registry', 'volume': '159', 'author': 'Brenner', 'year': '2020', 'journal-title': 'Gastroenterology'}, { 'issue': '1', 'key': '10.1016/j.ajt.2024.03.011_bib8', 'doi-asserted-by': 'crossref', 'first-page': '78', 'DOI': '10.1111/ajt.17199', 'article-title': 'Short-course early outpatient remdesivir prevents severe disease due ' 'to\xa0COVID-19 in organ transplant recipients during the omicron BA.2 ' 'wave', 'volume': '23', 'author': 'Solera', 'year': '2023', 'journal-title': 'Am J Transplant'}, { 'issue': '8', 'key': '10.1016/j.ajt.2024.03.011_bib9', 'doi-asserted-by': 'crossref', 'first-page': 'e266', 'DOI': '10.1016/S1473-3099(23)00357-2', 'article-title': 'Bivalent COVID-19 mRNA vaccine against omicron subvariants in ' 'immunocompromised patients', 'volume': '23', 'author': 'Solera', 'year': '2023', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.ajt.2024.03.011_bib10', 'doi-asserted-by': 'crossref', 'first-page': '30', 'DOI': '10.1016/S1473-3099(22)00816-7', 'article-title': 'Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB', 'volume': '23', 'author': 'Uraki', 'year': '2023', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '23', 'key': '10.1016/j.ajt.2024.03.011_bib11', 'doi-asserted-by': 'crossref', 'first-page': '2188', 'DOI': '10.1056/NEJMoa2116620', 'article-title': 'Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of ' 'Covid-19', 'volume': '386', 'author': 'Levin', 'year': '2022', 'journal-title': 'N\xa0Engl J Med'}, { 'key': '10.1016/j.ajt.2024.03.011_bib12', 'article-title': 'Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to ' 'neutralizing antibodies', 'author': 'Planas', 'year': '2022', 'journal-title': 'bioRxiv'}, { 'issue': '5', 'key': '10.1016/j.ajt.2024.03.011_bib13', 'doi-asserted-by': 'crossref', 'first-page': '528', 'DOI': '10.1016/S1473-3099(23)00208-6', 'article-title': 'Differential serum neutralisation of omicron sublineages in patients ' 'receiving prophylaxis with tixagevimab-cilgavimab', 'volume': '23', 'author': 'Solera', 'year': '2023', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '2', 'key': '10.1016/j.ajt.2024.03.011_bib14', 'doi-asserted-by': 'crossref', 'first-page': '279', 'DOI': '10.1016/j.cell.2022.12.018', 'article-title': 'Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB ' 'subvariants', 'volume': '186', 'author': 'Wang', 'year': '2023', 'journal-title': 'Cell'}, { 'issue': '1', 'key': '10.1016/j.ajt.2024.03.011_bib15', 'doi-asserted-by': 'crossref', 'first-page': '22', 'DOI': '10.1016/S1473-3099(22)00733-2', 'article-title': 'Omicron sublineage BQ.1.1 resistance to monoclonal antibodies', 'volume': '23', 'author': 'Arora', 'year': '2023', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '19', 'key': '10.1016/j.ajt.2024.03.011_bib16', 'doi-asserted-by': 'crossref', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'article-title': 'Remdesivir for the treatment of Covid-19 – final [report]', 'volume': '383', 'author': 'Beigel', 'year': '2020', 'journal-title': 'N\xa0Engl J Med'}, { 'issue': '15', 'key': '10.1016/j.ajt.2024.03.011_bib17', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N\xa0Engl J Med'}, { 'issue': '4', 'key': '10.1016/j.ajt.2024.03.011_bib18', 'doi-asserted-by': 'crossref', 'first-page': '480', 'DOI': '10.1053/j.ajkd.2022.01.001', 'article-title': 'Special considerations for Paxlovid treatment among transplant ' 'recipients with SARS-CoV-2 infection', 'volume': '79', 'author': 'Fishbane', 'year': '2022', 'journal-title': 'Am J Kidney Dis'}, { 'key': '10.1016/j.ajt.2024.03.011_bib19', 'series-title': 'Antiviral and Antibody Products Summary Recommendations', 'year': '2023'}, { 'issue': '12', 'key': '10.1016/j.ajt.2024.03.011_bib20', 'doi-asserted-by': 'crossref', 'first-page': '2193', 'DOI': '10.1093/cid/ciac324', 'article-title': 'Impact of vaccination and early monoclonal antibody therapy on ' 'coronavirus disease 2019 outcomes in organ transplant recipients during ' 'the omicron wave', 'volume': '75', 'author': 'Solera', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'issue': '3', 'key': '10.1016/j.ajt.2024.03.011_bib21', 'doi-asserted-by': 'crossref', 'first-page': 'e172', 'DOI': '10.1093/cid/ciac571', 'article-title': 'Clinical characteristics and outcomes of immunocompromised patients ' 'with coronavirus disease 2019 caused by the omicron variant: A ' 'prospective, observational study', 'volume': '76', 'author': 'Malahe', 'year': '2023', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ajt.2024.03.011_bib22', 'series-title': 'SARS-CoV-2 Genomic Surveillance in Ontario, March 24, 2023', 'year': '2023'}, { 'issue': '6', 'key': '10.1016/j.ajt.2024.03.011_bib24', 'doi-asserted-by': 'crossref', 'first-page': 'e304', 'DOI': '10.1097/TP.0000000000004126', 'article-title': 'Trends in COVID-19 outcomes in kidney transplant recipients during the ' 'period of Omicron variant predominance', 'volume': '106', 'author': 'Villanego', 'year': '2022', 'journal-title': 'Transplantation'}, { 'key': '10.1016/j.ajt.2024.03.011_bib25', 'article-title': 'Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants ' 'BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2', 'author': 'Qu', 'year': '2022', 'journal-title': 'bioRxiv'}, { 'issue': '4', 'key': '10.1016/j.ajt.2024.03.011_bib26', 'doi-asserted-by': 'crossref', 'first-page': '441', 'DOI': '10.1016/j.cmi.2022.12.004', 'article-title': 'Immunogenicity of COVID-19 vaccines in solid organ transplant ' 'recipients: a systematic review and meta-analysis', 'volume': '29', 'author': 'Chen', 'year': '2023', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '1', 'key': '10.1016/j.ajt.2024.03.011_bib27', 'doi-asserted-by': 'crossref', 'DOI': '10.1183/13993003.00502-2022', 'article-title': 'Efficacy of three COVID-19 vaccine doses in lung transplant recipients: ' 'a multicentre cohort study', 'volume': '61', 'author': 'Dauriat', 'year': '2023', 'journal-title': 'Eur Respir J'}, { 'issue': '7', 'key': '10.1016/j.ajt.2024.03.011_bib28', 'doi-asserted-by': 'crossref', 'first-page': '1800', 'DOI': '10.1111/ajt.15941', 'article-title': 'COVID-19 in solid organ transplant recipients: initial report from the ' 'US epicenter', 'volume': '20', 'author': 'Pereira', 'year': '2020', 'journal-title': 'Am J Transplant'}, { 'issue': '4', 'key': '10.1016/j.ajt.2024.03.011_bib29', 'doi-asserted-by': 'crossref', 'DOI': '10.1111/tid.13650', 'article-title': 'Immunosuppression in solid organ transplant recipients with Covid-19: ' 'more data, but still complicated', 'volume': '23', 'author': 'Heldman', 'year': '2021', 'journal-title': 'Transpl Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.ajt.2024.03.011_bib30', 'doi-asserted-by': 'crossref', 'first-page': '279', 'DOI': '10.1111/ajt.16840', 'article-title': 'Changing trends in mortality among solid organ transplant recipients ' 'hospitalized for COVID-19 during the course of the pandemic', 'volume': '22', 'author': 'Heldman', 'year': '2022', 'journal-title': 'Am J Transplant'}, { 'issue': '12', 'key': '10.1016/j.ajt.2024.03.011_bib31', 'doi-asserted-by': 'crossref', 'first-page': '3130', 'DOI': '10.1111/ajt.17128', 'article-title': 'Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with ' 'lower breakthrough infection risk in vaccinated solid organ transplant ' 'recipients during the omicron wave', 'volume': '22', 'author': 'Al Jurdi', 'year': '2022', 'journal-title': 'Am J Transplant'}, { 'issue': '4', 'key': '10.1016/j.ajt.2024.03.011_bib32', 'doi-asserted-by': 'crossref', 'first-page': '936', 'DOI': '10.1016/j.kint.2022.07.008', 'article-title': 'COVID-19 morbidity decreases\xa0with tixagevimab-cilgavimab preexposure ' 'prophylaxis in kidney transplant recipient nonresponders or low-vaccine ' 'responders', 'volume': '102', 'author': 'Kaminski', 'year': '2022', 'journal-title': 'Kidney Int'}], 'container-title': ['American Journal of Transplantation'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1600613524002077?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1600613524002077?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2024, 4, 30]], 'date-time': '2024-04-30T12:37:47Z', 'timestamp': 1714480667000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1600613524002077'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 3]]}, 'references-count': 31, 'alternative-id': ['S1600613524002077'], 'URL': 'http://dx.doi.org/10.1016/j.ajt.2024.03.011', 'relation': {}, 'ISSN': ['1600-6135'], 'issn-type': [{'value': '1600-6135', 'type': 'print'}], 'subject': [], 'published': {'date-parts': [[2024, 3]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Longitudinal outcomes of COVID-19 in solid organ transplant recipients from ' '2020 to 2023', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'American Journal of Transplantation', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ajt.2024.03.011', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society ' 'of Transplantation & American Society of Transplant Surgeons.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit